HB1340 Summary

• Requires the Director of Health to establish a temporary breakthrough therapy designation advisory council within three months of the FDA's approval of a designated breakthrough therapy for mental health or substance abuse disorders.

• Council membership includes the executive director of the office of wellness and resilience (chair), attorney general, director of law enforcement, health committee chairs from both legislative chambers, a licensed physician or advanced practice registered nurse, and other community representatives as recommended.

• Council must examine federal and state laws, regulations, clinical studies, and research regarding treatments for mental health conditions and substance abuse disorders receiving breakthrough therapy designation.

• Council shall submit a report of findings and recommendations, including any proposed legislation, to the legislature no later than one year after convening.

• Advisory council terminates upon withdrawal of the breakthrough therapy designation or the treatment's final FDA approval.